Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria:

Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy.
ECOG PS 0-1
70 years of age or older
Must have measurable disease
ANC > 1500, platelets > 100,000
Total bilirubin Able and willing to swallow and absorb oral medication
Able and willing to sign consent
Request archival diagnostic tissue for EGFR expression but not required

Exclusion Criteria:

Proteinuria as demonstrated by UPC ratio >/= 1.0
Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide)
Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic)
History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation
Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment.
Current, ongoing treatment with full dose warfarin or equivalent
Current(within 10 days)use of aspirin (> 325mg/day) or other NSAID with antiplatelet activity
History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD
Known CNS disease except for treated brain mets.
Squamous cell histology
Blood pressure > 150/100 that cannot be ameliorated with standard anti-hypertensives
History of hypertensive crisis or hypertensive encephalopathy
NYHA grade II or > CHF
History of MI within 6 months of enrollment
Major surgery, open biopsy, significant trauma within 28 days of enrollment
Pregnancy, lactation
Abdominal or other fistula, abcess, perforation